NSE - Free Realtime Quote INR

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

Compare
1,901.75 +4.75 (+0.25%)
As of 9:50 AM GMT+5:30. Market Open.
Currency in INR All numbers in thousands
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
484,978,100.00
477,584,500.00
432,788,700.00
384,264,200.00
332,330,800.00
Cost of Revenue
119,869,200.00
120,696,600.00
119,424,200.00
103,515,400.00
98,854,200.00
Gross Profit
365,108,900.00
356,887,900.00
313,364,500.00
280,748,800.00
233,476,600.00
Operating Expense
257,181,800.00
252,206,100.00
220,590,900.00
199,748,600.00
169,334,200.00
Operating Income
107,927,100.00
104,681,800.00
92,773,600.00
81,000,200.00
64,142,400.00
Net Non Operating Interest Income Expense
8,037,800.00
7,844,400.00
2,125,400.00
-1,273,500.00
700,400.00
Pretax Income
120,302,500.00
110,878,900.00
94,084,300.00
44,813,200.00
27,993,700.00
Tax Provision
15,236,000.00
14,394,500.00
8,475,900.00
10,755,000.00
5,146,900.00
Net Income Common Stockholders
103,894,600.00
95,763,800.00
84,735,800.00
32,727,300.00
29,038,200.00
Diluted NI Available to Com Stockholders
103,894,600.00
95,763,800.00
84,735,800.00
32,727,300.00
29,038,200.00
Basic EPS
43.30
39.90
35.30
13.60
12.10
Diluted EPS
43.30
39.90
35.30
13.60
12.10
Basic Average Shares
2,398,155.49
2,399,334.97
2,399,334.97
2,406,419.12
2,399,334.97
Diluted Average Shares
2,398,155.49
2,399,334.97
2,399,334.97
2,406,419.12
2,399,334.97
Rent Expense Supplemental
--
734,300.00
588,700.00
535,400.00
419,800.00
Total Expenses
377,051,000.00
372,902,700.00
340,015,100.00
303,264,000.00
268,188,400.00
Net Income from Continuing & Discontinued Operation
103,894,600.00
95,763,800.00
84,735,800.00
32,727,300.00
29,038,200.00
Normalized Income
104,661,228.90
99,337,186.72
86,386,834.68
67,435,683.21
61,957,564.60
Interest Income
--
10,229,100.00
3,845,400.00
5,533,700.00
2,111,300.00
Interest Expense
2,191,300.00
2,384,700.00
1,720,000.00
1,273,500.00
1,410,900.00
Net Interest Income
8,037,800.00
7,844,400.00
2,125,400.00
-1,273,500.00
700,400.00
EBIT
122,493,800.00
113,263,600.00
95,804,300.00
46,086,700.00
29,404,600.00
EBITDA
148,098,300.00
138,831,500.00
121,108,600.00
67,524,100.00
50,204,100.00
Reconciled Cost of Revenue
119,869,200.00
120,696,600.00
119,424,200.00
103,515,400.00
98,854,200.00
Reconciled Depreciation
25,604,500.00
25,567,900.00
25,304,300.00
21,437,400.00
20,799,500.00
Net Income from Continuing Operation Net Minority Interest
103,894,600.00
95,763,800.00
84,735,800.00
32,727,300.00
29,038,200.00
Total Unusual Items Excluding Goodwill
-877,800.00
-4,106,500.00
-1,814,500.00
-45,668,700.00
-40,335,400.00
Total Unusual Items
-877,800.00
-4,106,500.00
-1,814,500.00
-45,668,700.00
-40,335,400.00
Normalized EBITDA
148,976,100.00
142,938,000.00
122,923,100.00
113,192,800.00
90,539,500.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-111,171.10
-533,113.28
-163,465.32
-10,960,316.79
-7,416,035.40
3/31/2021 - 1/1/1996

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers